These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

764 related articles for article (PubMed ID: 15688597)

  • 1. Discovery, Development, and clinical applications of bortezomib.
    Jung L; Holle L; Dalton WS
    Oncology (Williston Park); 2004 Dec; 18(14 Suppl 11):4-13. PubMed ID: 15688597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacology, pharmacokinetics, and practical applications of bortezomib.
    Schwartz R; Davidson T
    Oncology (Williston Park); 2004 Dec; 18(14 Suppl 11):14-21. PubMed ID: 15688598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.
    Ludwig H; Khayat D; Giaccone G; Facon T
    Cancer; 2005 Nov; 104(9):1794-807. PubMed ID: 16178003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bortezomib: a valuable new antineoplastic strategy in multiple myeloma.
    Bladé J; Cibeira MT; Rosiñol L
    Acta Oncol; 2005; 44(5):440-8. PubMed ID: 16118077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bortezomib and its role in the management of patients with multiple myeloma.
    Orlowski RZ
    Expert Rev Anticancer Ther; 2004 Apr; 4(2):171-9. PubMed ID: 15056047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of bortezomib in B-cell non-Hodgkin's lymphoma.
    Wang M; Zhou Y; Zhang L; Nguyen CA; Romaguera J
    Expert Rev Anticancer Ther; 2006 Jul; 6(7):983-91. PubMed ID: 16831071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteasome inhibitors in the treatment of B-cell malignancies.
    Schenkein D
    Clin Lymphoma; 2002 Jun; 3(1):49-55. PubMed ID: 12141956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteasome inhibitor bortezomib for the treatment of multiple myeloma.
    Cavo M
    Leukemia; 2006 Aug; 20(8):1341-52. PubMed ID: 16810203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteasome inhibition: a new approach for the treatment of malignancies.
    Spano JP; Bay JO; Blay JY; Rixe O
    Bull Cancer; 2005 Nov; 92(11):E61-6, 945-52. PubMed ID: 16316823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma.
    Leonard JP; Furman RR; Coleman M
    Int J Cancer; 2006 Sep; 119(5):971-9. PubMed ID: 16557600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bortezomib: a novel therapy approved for multiple myeloma.
    Richardson PG; Anderson KC
    Clin Adv Hematol Oncol; 2003 Oct; 1(10):596-600. PubMed ID: 16258456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The proteasome: a novel target for anticancer therapy.
    Montagut C; Rovira A; Albanell J
    Clin Transl Oncol; 2006 May; 8(5):313-7. PubMed ID: 16760005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies.
    Caravita T; de Fabritiis P; Palumbo A; Amadori S; Boccadoro M
    Nat Clin Pract Oncol; 2006 Jul; 3(7):374-87. PubMed ID: 16826218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Proteasome inhibitors].
    Alexandre J
    Rev Med Interne; 2005 Oct; 26(10):812-5. PubMed ID: 16129520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies.
    Jackson G; Einsele H; Moreau P; Miguel JS
    Cancer Treat Rev; 2005 Dec; 31(8):591-602. PubMed ID: 16298074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteasome inhibition in multiple myeloma.
    Kropff M; Bisping G; Wenning D; Berdel WE; Kienast J
    Eur J Cancer; 2006 Jul; 42(11):1623-39. PubMed ID: 16820291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma.
    Richardson PG; Mitsiades C; Ghobrial I; Anderson K
    Curr Opin Oncol; 2006 Nov; 18(6):598-608. PubMed ID: 16988581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteasome inhibition for treatment of multiple myeloma: clinical update.
    Stadtmauer EA
    J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S10-5. PubMed ID: 19795531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell lymphoma.
    O'Connor OA
    Clin Lymphoma Myeloma; 2005 Nov; 6(3):191-9. PubMed ID: 16354324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical and clinical development of the proteasome inhibitor bortezomib in cancer treatment.
    Montagut C; Rovira A; Mellado B; Gascon P; Ross JS; Albanell J
    Drugs Today (Barc); 2005 May; 41(5):299-315. PubMed ID: 16082428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.